AstraZeneca reaches supply deal with Brazilian government to produce millions of doses of COVID shot
As COVID-19 continues to rampage across the globe, Brazil stands alongside the U.S. as the countries hardest hit with new infections and deaths. But AstraZeneca and its vaccine hopeful could be coming to save the day now that the drugmaker and Brazilian government have reached a new supply pact.
AstraZeneca and the government of Brazil have inked a deal valued at $127 million to produce doses of the University of Oxford’s adenovirus-based COVID-19 vaccine candidate, AZD1222, as the country combats a rising count of new infections.
Brazil—which trails only the U.S. in terms of total reported COVID-19 cases and deaths—will produce around 30 million doses of the vaccine, with roughly half that amount available by December, UPI reported.
AstraZeneca could not be reached for comment by press time on the details of the supply agreement, including how Brazil would produce doses of the vaccine.
As of Monday, the country had tallied 1.35 million cases of COVID-19 and nearly 58,000 deaths, according to case tracker Worldometers.
British drugmaker AstraZeneca’s newest supply agreement with Brazil comes only days after the company agreed to negotiations with the Japanese government for a similar production deal.